This article is for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. The content is provided by TotalHealthRD.com, a health information website operated by a Registered Dietitian Nutritionist — not a medical practice or healthcare facility. GLP-1 medications are prescription-only products that require evaluation by a licensed healthcare provider. Compounded medications are not FDA-approved finished drug products and are not reviewed by the FDA for safety, effectiveness, or quality before they reach patients. Individual results vary. Consult your physician before starting, stopping, or changing any prescription medication. Pricing information is current as of May 2026 — visit the official website for current pricing and terms. This is a Traffic-first article — no affiliate links are present.
By TotalHealthRD.com Editorial Team
Quick Answer: Novi is a telehealth GLP-1 program operated by Novi International LLC that connects eligible adults with US-licensed clinicians for potential semaglutide or tirzepatide prescriptions. Published offer-page pricing runs from $133/month (semaglutide) and $166/month (tirzepatide) as of May 2026, with all-inclusive costs covering medication, supplies, and clinician support. The program's FAQ describes month-to-month flexibility; the Terms of Service impose a three-month upfront commitment that is non-refundable — a discrepancy every prospective patient should read before enrolling. Separately, the FDA's April 30, 2026 proposal to close the 503B bulk compounding pathway for semaglutide and tirzepatide is an active regulatory development affecting the compounded GLP-1 market broadly.
What Is Novi?
Novi is a telehealth platform operated by Novi International LLC, incorporated at 30 N Gould St Ste R, Sheridan, Wyoming 82801. The program connects adults who pass an initial online eligibility quiz with US-licensed clinicians who independently evaluate whether a GLP-1 prescription is medically appropriate. Prescription is not guaranteed — that decision rests entirely with the reviewing clinician. Novi is not a pharmacy. It facilitates access to licensed US pharmacies that dispense the medication. It is not a healthcare provider.
The platform offers two compounded GLP-1 options: compounded semaglutide — which uses the same active ingredient as FDA-approved Ozempic and Wegovy — and compounded tirzepatide, which uses the same active ingredient as FDA-approved Mounjaro and Zepbound. Novi's own published materials are clear on this point: compounded medications are not FDA-approved finished drug products. That is the same active ingredient formulated by a different process, at different cost, and without the FDA's premarket review for safety, effectiveness, or quality.
The program structure is straightforward. Complete a three-minute online quiz, meet virtually with a Novi provider, and if prescribed, receive a 4-week supply with free 2-day shipping. The clinical team remains available for dose adjustments and questions throughout. Coaching is included at no additional cost, and Novi's published pricing is all-in — no separate membership fees layered on top of the medication cost.
Who This Is For
Novi is structured for adults who want cash-pay access to compounded GLP-1 weight loss medications without navigating insurance prior authorization processes or in-person physician visits. The platform is most practically suited to people who have already determined that GLP-1 pharmacotherapy aligns with their health goals, who want a telehealth intake process rather than a primary care referral, and who can commit to an upfront multi-month program cost.
The pricing structure — promotional offer-page rates starting at $133/month for semaglutide — is positioned well below the $1,349/month brand-name Wegovy cash-pay price. For patients without insurance coverage for weight loss medications, the cost differential is the primary reason telehealth compounding programs exist at all. Novi's published claims of 50,000+ patients served suggest meaningful market traction in this segment.
Who This Is NOT For
Novi is not appropriate for people who need insurance coverage for their GLP-1 medications. The program is explicitly cash-pay; insurance may reimburse for branded alternatives separately, but Novi does not coordinate prior authorization or insurance billing for the compounded medications it prescribes.
Novi is not appropriate for anyone who has a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 — the active ingredients in both semaglutide and tirzepatide carry a boxed FDA warning regarding thyroid C-cell tumor risk under these conditions, and are contraindicated accordingly. The prescribing clinician will screen for this, but patients should be aware before initiating intake.
Novi is also not suitable for anyone who needs flexible monthly cancellation at the moment of enrollment. The Terms of Service describe a three-month minimum upfront commitment — not the month-to-month flexibility the FAQ implies. That conflict is addressed in detail below, and it is a meaningful enough discrepancy that resolving it before enrollment is strongly recommended.
How Novi Works: The Mechanism Behind GLP-1 Medications
Semaglutide and tirzepatide are both injectable prescription medications that act on hormone signaling pathways involved in appetite and metabolic regulation. Semaglutide is a GLP-1 receptor agonist — it mimics glucagon-like peptide-1, a hormone the gut releases after eating that signals satiety to the brain, slows gastric emptying, and supports blood sugar regulation. The practical effect in weight management is reduced hunger signaling and a longer-lasting feeling of fullness after smaller meals.
Tirzepatide adds a second mechanism. It is a dual GIP/GLP-1 receptor agonist, engaging glucose-dependent insulinotropic polypeptide receptors alongside GLP-1 receptors. Clinical trials — the SURMOUNT-1 trial for tirzepatide and the STEP trials for semaglutide — have reported average weight reductions ranging from approximately 15% to 22.5% of body weight over 68 to 72 weeks in eligible populations. Novi's marketing references “up to 24%” body weight loss. That figure is attributed here exclusively to Novi's marketing materials; it exceeds the published tirzepatide trial mean averages and is not independently validated in this report.
Both medications are administered via weekly subcutaneous injection — typically self-administered into the abdomen, thigh, or upper arm. Dose is titrated upward over the initial weeks to reduce gastrointestinal side effects while approaching therapeutic dose. For a more detailed explanation of the mechanism and research framework, see How GLP-1 Medications Work: A 2026 Research Overview.
What We Verified
The following represents independent verification work completed for this report as of May 2026.
Pricing: Compounded semaglutide listed at “from $133/month” and compounded tirzepatide at “from $166/month” on the Novi offer page (joinnovi.com/offer-v6-low). These are promotional pricing page figures; the Terms of Service state that Novi may adjust pricing at any time. Confirmed May 2026.
Cancellation terms — conflict documented: The Novi FAQ states the program is “month-to-month with no minimum commitments or long-term contracts.” The Novi Terms of Service, Section VII, states: “Subscription based Products and/or Services require a minimum 3-month commitment.” The first three months are billed upfront and are non-refundable, with the exception of prescriptions deemed medically inappropriate before dispensing. To cancel ongoing charges after the three-month period, cancellation must occur at least 15 days before the next monthly processing date. Recommendation: Email [email protected] before enrolling to confirm which cancellation structure applies to your specific enrollment type.
Refund policy: “All Products are non-refundable” per Terms of Service, Section IV. One published exception: if a provider determines the prescription is medically inappropriate before it is dispensed, the initial payment is refunded. Confirmed.
Contact information: [email protected], 214-427-4553. Mailing address: Novi International LLC, 30 N Gould St Ste R, Sheridan, WY 82801. Confirmed from source.
Provider credentials: Named providers in source material include Daniel Funsch MD (American Board of Emergency Medicine), Michael Wasef MD (American Board of Internal Medicine), Kristine Clements NP (board certified FNP, 25 years experience), Takashi Nakamura MD (American Board of Emergency Medicine), Kimberli Hastings NP, and Theresa Vergara NP (DNP). Confirmed from source.
Pharmacy partners: Novi's FAQ states medications are “sourced from trusted, licensed U.S. pharmacies.” Specific pharmacy partner names are not disclosed in published source materials. The specific compounding pathway (503A or 503B) is not disclosed. Unconfirmed — noted.
LegitScript certification: Cited in third-party reporting on the program as a legitimacy signal. Not independently verified via the LegitScript registry for this report — readers may verify at legitscript.com.
FDA regulatory status (May 2026): The FDA removed semaglutide from its drug shortage list in February 2025 and tirzepatide in October 2024. On April 30, 2026, the FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B Bulk Drug Substances List (Federal Register docket 2026-08552), finding no clinical need for large-scale compounding absent a shortage. The public comment period is open through June 29, 2026. 503A patient-specific compounding by state-licensed pharmacies remains legal. Confirmed via FDA sources.
Pricing and Policies in Detail
The all-in monthly cost structure is a meaningful differentiator for Novi relative to some competitors. Medication, supplies, free 2-day shipping, ongoing clinician access, and coaching are bundled — no separate membership fee. The promotional offer-page pricing starts at $133/month for compounded semaglutide and $166/month for compounded tirzepatide.
The three-month upfront billing structure means the actual enrollment cost is approximately $399 at the semaglutide promotional rate and approximately $498 at the tirzepatide rate — not a single month's charge. This is the figure to budget before starting the intake quiz, not the per-month figure from the marketing page.
The refund exception for medically inappropriate prescriptions applies only when the provider determines a prescription cannot be written. If a prescription is written, dispensed, and shipped, no refund is available. The Terms of Service also include language noting that false credit card disputes “will be aggressively defended” — a clause worth reading before any charge concern arises.
Insurance does not cover Novi's compounded medications. The FAQ notes that insurance may reimburse for branded options separately; that is a coordination the patient handles outside of Novi's program.
The FDA's April 2026 Ruling: What It Means for Compounded GLP-1 Access
On April 30, 2026, the FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B Bulk Drug Substances List. The agency's stated rationale: FDA-approved versions of these drugs are available, and the clinical need that would justify large-scale bulk compounding has not been established. This proposal, published in Federal Register docket 2026-08552, closes the primary regulatory pathway that allowed high-volume compounding facilities to produce semaglutide and tirzepatide at scale during the shortage years of 2022-2025.
What this means practically depends on which compounding pathway Novi's pharmacy partners use. 503A patient-specific compounding — where a licensed pharmacy prepares a medication for an individual patient based on a valid prescription — operates under a separate legal framework and is not affected by the 503B Bulks List proposal. If Novi's pharmacies operate under 503A, the current program is not directly disrupted by this proposal. If any supply chain relies on 503B outsourcing facilities, the regulatory picture is more complex.
Because Novi does not publicly disclose its pharmacy partner names or the specific compounding pathway used, this question cannot be answered from published information alone. The practical step for a prospective patient: email [email protected] and ask directly which pharmacy(ies) fulfill prescriptions and whether they operate under 503A or 503B. That answer provides meaningful context given the current regulatory environment. For a deeper analysis of the compounded vs. FDA-approved question, see Compounded vs. FDA-Approved GLP-1: What the Evidence Shows.
The Cancellation Conflict: Reading Both Documents
Most prospective Novi patients will read the FAQ and come away believing they can cancel anytime with no commitment. That is what the FAQ says. The Terms of Service tell a different story, and the Terms of Service are the legally binding document.
The Novi FAQ states: “You can cancel your Novi subscription at any time. Our program is month-to-month with no minimum commitments or long-term contracts, so cancellation is simple and flexible.”
Section VII of the Novi Terms of Service states: “Subscription based Products and/or Services require a minimum 3-month commitment as We incur significant upfront cost to provide these Products and/or Services to you. By enrolling in Subscription Services, you agree to pay for a minimum of three (3) consecutive months of Service.” It continues: the first month's fee and the following two months' fees — three months total — are charged at the time of purchase and are non-refundable unless the prescription is medically inappropriate.
These two positions are not reconcilable. Before enrolling, contact Novi's support team directly at [email protected] or 214-427-4553 and ask which cancellation structure governs your specific enrollment. Get the answer in writing. The ToS language indicates that false credit card disputes will be “aggressively defended and customers who attempt to dispute charges to circumvent the 3-month commitment will be sent to collections and/or have further legal action pursued. That is a direct quotation from the Novi Terms of Service, and it reflects the stakes of misunderstanding the enrollment terms.
Final Assessment
Novi is a structurally coherent telehealth GLP-1 program. The provider credentials are named and board-certified. The all-in pricing model is transparent on the offer page. The three-step process is straightforward. The FAQ cancellation language is the primary red flag—not because cancellation is impossible, but because the Terms of Service describe substantially different terms than the FAQ implies, and resolving that conflict requires direct communication with Novi's support team before committing.
The FDA's April 2026 regulatory proposal adds a layer of uncertainty to the compounded GLP-1 market that applies to Novi and its competitors equally. It does not make Novi's program illegal today — 503A compounding remains legal — but it does make transparency about pharmacy sourcing a reasonable question to ask before enrollment.
For anyone evaluating this program: read both the FAQ and the full Terms of Service, confirm the specific cancellation terms that apply to your enrollment in writing, ask which pharmacy(ies) fulfill the prescription and under which compounding framework, and discuss the medication with your own physician before starting, particularly if you take medications for thyroid conditions, pancreatitis history, diabetes management, or cardiovascular disease.
For more context on how these medications work: How GLP-1 Medications Work: A 2026 Research Overview. For safety and interaction information: GLP-1 Safety Guide 2026. For a side-by-side comparison of Novi with other telehealth programs: GLP-1 Telehealth Comparison 2026: Hims, LifeMD, Novi, Ro.
Frequently Asked Questions
Is Novi GLP-1 a legitimate telehealth program?
Novi is operated by Novi International LLC with published contact information, named board-certified providers, and third-party legitimacy signals including LegitScript certification referenced in third-party reporting. The program connects patients with licensed clinicians who independently evaluate prescription eligibility. It is not a pharmacy or healthcare provider. Legitimacy signals are present; the cancellation term discrepancy between the FAQ and Terms of Service is the primary concern a prospective patient should resolve before enrolling. Email [email protected] before purchase to confirm which cancellation structure applies.
What does Novi GLP-1 cost per month?
Offer-page pricing as of May 2026: compounded semaglutide from $133/month, compounded tirzepatide from $166/month. These are all-inclusive prices covering medication, supplies, shipping, clinician support, and coaching. The three-month upfront billing commitment in the Terms of Service means actual enrollment cost is approximately $399 for semaglutide or $498 for tirzepatide at the published promotional rates. Pricing is subject to change per the Terms of Service.
Can I cancel Novi anytime?
The FAQ says yes — month-to-month, no commitment. The Terms of Service say no — three months minimum, billed upfront, non-refundable. These two documents conflict. Contact Novi at [email protected] before enrolling to confirm the terms governing your specific enrollment in writing. Cancellation to stop ongoing charges after the three-month commitment requires notice at least 15 days before the next billing date.
Does Novi use FDA-approved GLP-1 medications?
No. Novi prescribes compounded semaglutide and compounded tirzepatide — not FDA-approved finished drug products. The active ingredients are the same as Wegovy and Zepbound, but compounded medications are not reviewed by the FDA for safety, effectiveness, or quality before they reach patients. Novi's own materials state this explicitly. The FDA's April 30, 2026 proposal adds regulatory uncertainty to the 503B compounding pathway; 503A patient-specific compounding by licensed pharmacies remains legal as of May 2026.
What are the side effects of semaglutide and tirzepatide?
The most common side effects are gastrointestinal — nausea, vomiting, diarrhea, constipation — most pronounced during dose escalation. More serious risks include pancreatitis, gallbladder disease, and thyroid C-cell tumor risk (boxed warning). These medications are contraindicated in individuals with a personal or family history of medullary thyroid carcinoma or MEN2 syndrome. Full safety context is available in the GLP-1 Safety Guide 2026.
This article is for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. The content is provided by TotalHealthRD.com, a health information website operated by a Registered Dietitian Nutritionist — not a medical practice or healthcare facility. GLP-1 medications are prescription-only products requiring evaluation by a licensed healthcare provider. Compounded medications are not FDA-approved finished drug products. Individual results vary significantly. This is a Traffic-first article — no affiliate links are present. Consult your physician before starting, stopping, or changing any prescription medication.